Based on the innovative correlation between PTEN and PLK1, detecting soluble PLK1 using the whole blood samples from pancreatic cancer patients and accessible techniques such as Western blots and ELISA might be an innovative therapeutic strategy with a blockade of PTEN for patients already diagnosed with pancreatic cancer or such patients who have exhausted all other options. The gene discussed is PTEN; the disease is familial pancreatic carcinoma.